Home

Latest news

HEMA Biologics Announces FDA Approval of SEVENFACT® [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors

Read More

Contact Medical Affairs

Healthcare professionals, learn more about the science behind HEMA Biologics investigational treatments for the rarest bleeding disorders.

Read More

Join the brigade!

Check out our new app, and become Sergeant Factor in this exciting interactive experience.

Read More

“We aspire to support patients living with these disorders, partner with the broader community that cares for them, and bring meaningful treatments and services to help better their daily lives.”